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Etiology of SVC Syndrome and its Role in 
Determining Best Treatment Approach 
A Case Report




• Endovascular stenting is the treatment of choice for 
thrombotic causes of SVCS, which is becoming 
more common due to the increased use of CVCs. • To discuss the role of etiology in determining the best initial treatment for SVC syndrome (SVCS).
• To outlines a unique management approach for a 
patient that represents the changing demographics 
of SVCS causes.
CASE PRESENTATION
• Obstruction of the Super Vena Cava (SVC) can result 
in symptoms, such as facial plethora and swelling.
• It can be due to a variety of underlying causes besides 
lung malignancies. 
• The rates of underlying causes have which have 
changed over time. 
• The underlying etiology is used to determine the best 
management strategy.
OBJECTIVE
• A 73-year-old male with end-stage renal disease 
(ESRD) and metastatic carcinoma of the colon 
presented with swelling of the jaw, neck, and 
tongue. 
• CT scan showed chronic thrombosis of the SVC and 
bilateral brachiocephalic veins. 
• He had been receiving hemodialysis and 
chemotherapy through central venous catheters 
(CVCs) that transversed the SVC and terminated in 
the right atrium, resulting in venous stasis. 
• Treatment involved double-barrel stent 
reconstruction of the SVC with temporary 
repositioning of the chemotherapy port catheter and 
exchange of the hemodialysis catheter.
• He experienced relief of symptoms and was able to 
continue his hemodialysis and chemotherapy 
appointments.
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Figure 3: Stenosis of SVC
Figure 4: Patency of SVC following 
deployment of bilateral kissing stents 
with replaced CVCs• For cases of SVCS due to underlying lung malignancies, which has been and 
remains the most common cause, endovascular stenting is reserved as a palliative 
measure when treatment of a refractory malignancy fails to resolve the obstruction 
and for when symptoms are severe because most cases are not life-threatening. 
• However, increased use of CVCs has caused a rise in SVCS due to thrombosis, for 
which stenting is the first-line treatment. Rare causes of SVCS that may require 
surgical correction include mediastinal fibrosis and thymomas. 
• Of the few previously published case reports that depict bilateral SVC stenting and 
temporary repositioning of a CVC, they all describe cases due to lung malignancies 
or mediastinal fibrosis. 
• Outlining this case presentation can increase awareness of thrombotic stenosis as 
an increasingly common cause of SVCS, which may occur in patients with a 
broader range of underlying conditions, ages, and life expectancies and require a 
wider array of physicians to be knowledgeable of management strategies. 
• While stenting technology has improved dramatically since its inception, follow-up 
on stent patency will help determine if expanding treatment for lower acuity cases is 
beneficial.
Figure 2: Etiology of SVCS change with Time




Malignancy still  most common 
cause but thrombotic causes 
due to indwelling CVCs now 
responsible for 35% of SVCS 
cases in US
2/3 of cases due to: 
syphilis (aortic 
aneurysm) or TB 
(mediastinal disease)
Figure 1: Etiology and Most Common Treatment Strategy
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